Will an Alzheimer's drug demonstrating 50%+ cognitive decline reduction receive approval before 2028?

The FDA or EMA must approve an Alzheimer's disease treatment that demonstrated at least 50% reduction in cognitive decline (vs placebo on CDR-SB or ADAS-Cog) in Phase 3 trials before January 1, 2028. Based on regulatory approval documents and published trial results.